Uptravi

RSS

selexipag

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Uptravi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Uptravi.

For practical information about using Uptravi, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 01/07/2022

Authorisation details

Product details
Name
Uptravi
Agency product number
EMEA/H/C/003774
Active substance
Selexipag
International non-proprietary name (INN) or common name
selexipag
Therapeutic area (MeSH)
Hypertension, Pulmonary
Anatomical therapeutic chemical (ATC) code
B01AC27
Publication details
Marketing-authorisation holder
Janssen Cilag International NV
Revision
13
Date of issue of marketing authorisation valid throughout the European Union
12/05/2016
Contact address

Turnhoutseweg 30
B 2340 Beerse
Belgium

Product information

19/05/2022 Uptravi - EMEA/H/C/003774 - II/0034

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.

Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating